Articles

Erasmus Medical Center in Rotterdam and NRG PALLAS teamed up last years within FIELD-LAB to realise a study on the stability and efficacy of different ligands in combination with Lead-212 for the treatment of NETs. And the results were promising.

A decade ago, it was claimed that alpha-emitters are indispensable when it comes to optimisation of strategies for tumour therapy. Over time, this robust statement has become increasingly relevant, which has resulted in research aiming to develop alpha therapy which can be used in the clinic to substantially improve outcomes for cancer patients. This is exactly what healthcare entrepreneur Jan van Bodegom, MD will present at the 3rd Annual Targeted Radiopharmaceuticals (TRP) Summit in Berlin between 7 and 9 December 2021.